Size | Price | Stock | Qty |
---|---|---|---|
1mg |
|
||
2mg |
|
||
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
Other Sizes |
|
Purity: ≥98%
ln Vitro |
The co-knockdown therapy of ADAM10/17 or GW280264X resulted in a considerable reduction in GS-7 cell growth [2].
|
---|---|
Cell Assay |
Cell Viability Assay[2]
Cell Types: Glioblastoma-initiating cells (GIC) GS-7 cells Tested Concentrations: 0.1, 1, and 3 µM Incubation Duration: 48 hrs (hours) Experimental Results: The proliferation of GIC was inhibited by inhibiting ADAM10 and ADAM17. |
Animal Protocol |
Animal/Disease Models: C57BL/6 mice [3]
Doses: 100 μg/kg Route of Administration: intraperitoneal (ip) injection; pharmacological inhibition of ADAM10 and ADAM17 can improve functional recovery after injury (SCI) [3]. Starting 4 hrs (hrs (hours)) after surgery, one time/day for one week. Experimental Results: Compared with the control group, functional recovery was Dramatically improved. |
References |
[1]. Christian Hundhausen, et al. The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion. Blood. 2003 Aug 15;102(4):1186-95.
[2]. Fabian Wolpert, et al. A disintegrin and metalloproteinases 10 and 17 modulate the immunogenicity of glioblastoma-initiating cells. Neuro Oncol. 2014 Mar;16(3):382-91. [3]. Daniela Sommer, et al. ADAM17-deficiency on microglia but not on macrophages promotes phagocytosis and functional recovery after spinal cord injury. Brain Behav Immun. 2019 Aug;80:129-145. |
Molecular Formula |
C28H41N5O6S
|
---|---|
Molecular Weight |
575.725
|
Exact Mass |
575.2778
|
Elemental Analysis |
C, 58.41; H, 7.18; N, 12.16; O, 16.67; S, 5.57
|
CAS # |
866924-39-2
|
SMILES |
O=C(OCC1=CC=CC=C1)NCCCC[C@H](NC([C@H](CC(C)C)[C@@H](N(C=O)O)CCC)=O)C(NC2=NC=CS2)=O
|
Chemical Name |
Benzyl N-[(5S)-5-[[(2R,3S)-3-(Formylhydroxyamino)-2-(2-methylpropyl)-1-oxohexyl]amino]-6-oxo-6-(2-thiazolylamino)hexyl]-carbamate
|
Synonyms |
GW280264 GW-280264 GW 280264 GW280264X GW-280264X GW 280264X
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ~125 mg/mL (~217.12 mM)
|
---|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.7369 mL | 8.6846 mL | 17.3693 mL | |
5 mM | 0.3474 mL | 1.7369 mL | 3.4739 mL | |
10 mM | 0.1737 mL | 0.8685 mL | 1.7369 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.